Home・Aktien・United Therapeutics Corp

United Therapeutics Corp

Geschlossen

BrancheGesundheitswesen

536.85 1.36

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

522.44

Max

540.58

Schlüsselkennzahlen
By Trading Economics
Einkommen	-89M 275M
Verkäufe	-8.7M 782M
KGV Branchendurchschnitt	19.108 68.51
EPS	5.82
Gewinnspanne	35.176
Angestellte	1,400
EBITDA	-180M 344M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+22.93% upside

Dividenden
By Acuity
Nächstes Ergebnis	28. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 26B
Vorheriger Eröffnungskurs	535.49
Vorheriger Schlusskurs	536.85

Nachrichtenstimmung

By Acuity

40%

60%

120 / 340 Ranking in Healthcare

United Therapeutics Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

United Therapeutics Corp Prognose

Kursziel

By TipRanks

22.93% Vorteil

12-Monats-Prognose

Durchschnitt 655.13 USD 22.93%

Hoch 714 USD

Tief 515 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für United Therapeutics Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für United Therapeutics Corp – Dist abgegeben haben.

Stimmung

By Acuity

120 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.